International Journal of Antimicrobial Agents
Volume 35, Issue 4 , Pages 316-321 , April 2010

Molecular epidemiology of Escherichia coli producing CTX-M β-lactamases: the worldwide emergence of clone ST131 O25:H4

  • Gisele Peirano

      Affiliations

    • Division of Microbiology, Calgary Laboratory Services, Canada
    • Department of Pathology & Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada
    • ,
  • Johann D.D. Pitout

      Affiliations

    • Division of Microbiology, Calgary Laboratory Services, Canada
    • Department of Pathology & Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada
    • Department of Microbiology and Infectious Diseases, University of Calgary, Calgary, Alberta, Canada
    • Corresponding Author InformationCorresponding author. Present address: Calgary Laboratory Services, #9, 3535 Research Road NW, Calgary, Alberta, Canada T2L 2K8. Tel.: +1 403 770 3309; fax: +1 403 770 3347.

Received 7 August 2009 ,Accepted 6 November 2009.

References 

  1. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev. 2005;18:657–686
  2. Nicolas-Chanoine MH, Jarlier V. Extended-spectrum β-lactamases in long-term-care facilities. Clin Microbiol Infect. 2008;14(Suppl. 1):111–116[Erratum in: Clin Microbiol Infect 2008;14(Suppl. 5):21–4]
  3. Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and economic impact of bacteremia with extended-spectrum-β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2006;50:1257–1262
  4. Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori B, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother. 2007;51:1987–1994[Erratum in: Antimicrob Agents Chemother 2007;51:3469]
  5. Talbot GH, Bradley J, Edwards JE, Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis. 2006;42:657–668
  6. Matsumoto Y, Ikeda F, Kamimura T, Yokota Y, Mine Y. Novel plasmid-mediated β-lactamase from Escherichia coli that inactivates oxyimino-cephalosporins. Antimicrob Agents Chemother. 1988;32:1243–1246
  7. Radice M, Power P, Di Conza J, Gutkind G. Early dissemination of CTX-M-derived enzymes in South America. Antimicrob Agents Chemother. 2002;46:602–604
  8. Rossi A, Lopardo H, Woloj M, Picandet AM, Mariño M, Galds M, et al. Non-typhoid Salmonella spp. resistant to cefotaxime. J Antimicrob Chemother. 1995;36:697–702
  9. Canton R, Coque TM. The CTX-M β-lactamase pandemic. Curr Opin Microbiol. 2006;9:466–475
  10. Pitout JD, Laupland KB. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8:159–166
  11. Pitout JD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community. J Antimicrob Chemother. 2005;56:52–59
  12. Rossolini GM, D’Andrea MM, Mugnaioli C. The spread of CTX-M-type extended-spectrum β-lactamases. Clin Microbiol Infect. 2008;14(Suppl. 1):33–41
  13. Poirel L, Lartigue MF, Decousser JW, Nordmann P. ISEcp1B-mediated transposition of blaCTX-M in Escherichia coli. Antimicrob Agents Chemother. 2005;49:447–450
  14. Poirel L, Naas T, Nordmann P. Genetic support of extended-spectrum β-lactamases. Clin Microbiol Infect. 2008;14(Suppl. 1):75–81
  15. Poirel L, Decousser JW, Nordmann P. Insertion sequence ISEcp1B is involved in expression and mobilization of a blaCTX-M β-lactamase gene. Antimicrob Agents Chemother. 2003;47:2938–2945
  16. Carattoli A. Resistance plasmid families in Enterobacteriaceae. Antimicrob Agents Chemother. 2009;53:2227–2238
  17. Bonnet R. Growing group of extended-spectrum β-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother. 2004;48:1–14
  18. Laupland KB, Church DL, Vidakovich J, Mucenski M, Pitout JD. Community-onset extended-spectrum β-lactamase (ESBL) producing Escherichia coli: importance of international travel. J Infect. 2008;57:441–448
  19. Rodriguez-Bano J, Navarro MD. Extended-spectrum β-lactamases in ambulatory care: a clinical perspective. Clin Microbiol Infect. 2008;14(Suppl. 1):104–110
  20. Karim A, Poirel L, Nagarajan S, Nordmann P. Plasmid-mediated extended-spectrum β-lactamase (CTX-M-3 like) from India and gene association with insertion sequence ISEcp1. FEMS Microbiol Lett. 2001;201:237–241
  21. Poirel L, Gniadkowski M, Nordmann P. Biochemical analysis of the ceftazidime-hydrolysing extended-spectrum β-lactamase CTX-M-15 and of its structurally related β-lactamase CTX-M-3. J Antimicrob Chemother. 2002;50:1031–1034
  22. Novais A, Canton R, Moreira R, Peixe L, Baquero F, Coque TM. Emergence and dissemination of Enterobacteriaceae isolates producing CTX-M-1-like enzymes in Spain are associated with IncFII (CTX-M-15) and broad-host-range (CTX-M-1, -3, and -32) plasmids. Antimicrob Agents Chemother. 2007;51:796–799
  23. Boyd DA, Tyler S, Christianson S, McGeer A, Muller MP, Willey BM, et al. Complete nucleotide sequence of a 92-kilobase plasmid harboring the CTX-M-15 extended-spectrum β-lactamase involved in an outbreak in long-term-care facilities in Toronto, Canada. Antimicrob Agents Chemother. 2004;48:3758–3764
  24. Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, et al. Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med. 2006;12:83–88
  25. Livermore DM, Canton R, Gniadkowski M, Nordmann P, Rossolini GM, Arlet G, et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother. 2007;59:165–174
  26. Hawkey PM. Prevalence and clonality of extended-spectrum β-lactamases in Asia. Clin Microbiol Infect. 2008;14(Suppl. 1):159–165
  27. Lewis JS, Herrera M, Wickes B, Patterson JE, Jorgensen JH. First report of the emergence of CTX-M-type extended-spectrum β-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system. Antimicrob Agents Chemother. 2007;51:4015–4021
  28. Mulvey MR, Bryce E, Boyd D, Ofner-Agostini M, Christianson S, Simor AE, et al. Ambler class A extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella spp. in Canadian hospitals. Antimicrob Agents Chemother. 2004;48:1204–1214
  29. Villegas MV, Kattan JN, Quinteros MG, Casellas JM. Prevalence of extended-spectrum β-lactamases in South America. Clin Microbiol Infect. 2008;14(Suppl. 1):154–158
  30. Zong Z, Partridge SR, Thomas L, Iredell JR. Dominance of blaCTX-M within an Australian extended-spectrum β-lactamase gene pool. Antimicrob Agents Chemother. 2008;52:4198–4202
  31. Cantón R, Novais A, Valverde A, Machado E, Peixe L, Baquero F, et al. Prevalence and spread of extended-spectrum β-lactamase-producing Enterobacteriaceae in Europe. Clin Microbiol Infect. 2008;14(Suppl. 1):144–153
  32. Ensor VM, Shahid M, Evans JT, Hawkey PM. Occurrence, prevalence and genetic environment of CTX-M β-lactamases in Enterobacteriaceae from Indian hospitals. J Antimicrob Chemother. 2006;58:1260–1263
  33. Gupta V, Datta P. Extended-spectrum β-lactamases (ESBL) in community isolates from North India: frequency and predisposing factors. Int J Infect Dis. 2007;11:88–89
  34. Moubareck C, Daoud Z, Hakimé NI, Hamzé M, Mangeney N, Matta H, et al. Countrywide spread of community- and hospital-acquired extended-spectrum β-lactamase (CTX-M-15)-producing Enterobacteriaceae in Lebanon. J Clin Microbiol. 2005;43:3309–3313
  35. Blomberg B, Jureen R, Manji KP, Tamim BS, Mwakagile DS, Urassa WK, et al. High rate of fatal cases of pediatric septicemia caused by Gram-negative bacteria with extended-spectrum β-lactamases in Dar es Salaam, Tanzania. J Clin Microbiol. 2005;43:745–749
  36. Gangoue-Pieboji J, Miriagou V, Vourli S, Tzelepi E, Ngassam P, Tzouvelekis LS. Emergence of CTX-M-15-producing enterobacteria in Cameroon and characterization of a blaCTX-M-15-carrying element. Antimicrob Agents Chemother. 2005;49:441–443
  37. Mamlouk K, Boutiba-Ben Boubaker I, Gautier V, Vimont S, Picard B, Ben Redjeb S, et al. Emergence and outbreaks of CTX-M β-lactamase-producing Escherichia coli and Klebsiella pneumoniae strains in a Tunisian hospital. J Clin Microbiol. 2006;44:4049–4056
  38. Touati A, Benallaoua S, Djoudi F, Madoux J, Brasme L, De Champs C. Characterization of CTX-M-15-producing Klebsiella pneumoniae and Escherichia coli strains isolated from hospital environments in Algeria. Microb Drug Resist. 2007;13:85–89
  39. Bush K. Extended-spectrum beta-lactamases in North America, 1987–2006. Clin Microbiol Infect. 2008;14(Suppl. 1):134–143
  40. Moland ES, Black JA, Hossain A, Hanson ND, Thomson KS, Pottumarthy S. Discovery of CTX-M-like extended-spectrum β-lactamases in Escherichia coli isolates from five US States. Antimicrob Agents Chemother. 2003;47:2382–2383
  41. Castanheira M, Mendes RE, Rhomberg PR, Jones RN. Rapid emergence of blaCTX-M among Enterobacteriaceae in U.S. medical centers: molecular evaluation from the MYSTIC Program (2007). Microb Drug Resist. 2008;14:211–216
  42. Pitout JD, Church DL, Gregson DB, Chow BL, McCracken M, Mulvey MR, et al. Molecular epidemiology of CTX-M-producing Escherichia coli in the Calgary Health Region: emergence of CTX-M-15-producing isolates. Antimicrob Agents Chemother. 2007;51:1281–1286
  43. Pitout JD, Laupland KB, Church DL, Menard ML, Johnson JR. Virulence factors of Escherichia coli isolates that produce CTX-M-type extended-spectrum β-lactamases. Antimicrob Agents Chemother. 2005;49:4667–4670
  44. Pallecchi L, Malossi M, Mantella A, Gotuzzo E, Trigoso C, Bartoloni A, et al. Detection of CTX-M-type β-lactamase genes in fecal Escherichia coli isolates from healthy children in Bolivia and Peru. Antimicrob Agents Chemother. 2004;48:4556–4561
  45. Valenzuela de Silva EM, Mantilla Anaya JR, Reguero Reza MT, González Mejía EB, Pulido Manrique IY, Darío Llerena I, et al. Detection of CTX-M-1, CTX-M-15, and CTX-M-2 in clinical isolates of Enterobacteriaceae in Bogota, Colombia. J Clin Microbiol. 2006;44:1919–1920
  46. Edelstein M, Pimkin M, Palagin I, Edelstein I, Stratchounski L. Prevalence and molecular epidemiology of CTX-M extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Russian hospitals. Antimicrob Agents Chemother. 2003;47:3724–3732
  47. Woodford N, Ward ME, Kaufmann ME, Turton J, Fagan EJ, James D, et al. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum β-lactamases in the UK. J Antimicrob Chemother. 2004;54:735–743
  48. Oteo J, Navarro C, Cercenado E, Delgado-Iribarren A, Wilhelmi I, Orden B, et al. Spread of Escherichia coli strains with high-level cefotaxime and ceftazidime resistance between the community, long-term care facilities, and hospital institutions. J Clin Microbiol. 2006;44:2359–2366
  49. Eisner A, Fagan EJ, Feierl G, Kessler HH, Marth E, Livermore DM, et al. Emergence of Enterobacteriaceae isolates producing CTX-M extended-spectrum β-lactamase in Austria. Antimicrob Agents Chemother. 2006;50:785–787
  50. Mugnaioli C, Luzzaro F, De Luca F, Brigante G, Perilli M, Amicosante G, et al. CTX-M-type extended-spectrum β-lactamases in Italy: molecular epidemiology of an emerging countrywide problem. Antimicrob Agents Chemother. 2006;50:2700–2706
  51. Mendonca N, Leitao J, Manageiro V, Ferreira E, Canica M. Spread of extended-spectrum β-lactamase CTX-M-producing Escherichia coli clinical isolates in community and nosocomial environments in Portugal. Antimicrob Agents Chemother. 2007;51:1946–1955
  52. Galas M, Decousser JW, Breton N, Godard T, Allouch PY, Pina P. Nationwide study of the prevalence, characteristics, and molecular epidemiology of extended-spectrum-β-lactamase-producing Enterobacteriaceae in France. Antimicrob Agents Chemother. 2008;52:786–789
  53. Fang H, Ataker F, Hedin G, Dornbusch K. Molecular epidemiology of extended-spectrum β-lactamases among Escherichia coli isolates collected in a Swedish hospital and its associated health care facilities from 2001 to 2006. J Clin Microbiol. 2008;46:707–712
  54. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol. 1995;33:2233–2239
  55. Lau SH, Cheesborough J, Kaufmann ME, Woodford N, Dodgson AR, Dodgson KJ, et al. Rapid identification of uropathogenic Escherichia coli of the O25:H4-ST131 clonal lineage using the DiversiLab repetitive sequence-based PCR system. Clin Microbiol Infect. 2009 Mar 21;
  56. Pitout JD, Campbell L, Church DL, Wang PW, Guttman DS, Gregson DB. Using a commercial DiversiLab semiautomated repetitive sequence-based PCR typing technique for identification of Escherichia coli clone ST131 producing CTX-M-15. J Clin Microbiol. 2009;47:1212–1215
  57. Woodford N. Successful, multiresistant bacterial clones. J Antimicrob Chemother. 2008;61:233–234
  58. Lavollay M, Mamlouk K, Frank T, Akpabie A, Burghoffer B, Ben Redjeb S, et al. Clonal dissemination of a CTX-M-15 β-lactamase-producing Escherichia coli strain in the Paris area, Tunis, and Bangui. Antimicrob Agents Chemother. 2006;50:2433–2438
  59. Gonullu N, Aktas Z, Kayacan CB, Salcioglu M, Carattoli A, Yong DE, et al. Dissemination of CTX-M-15 β-lactamase genes carried on Inc FI and FII plasmids among clinical isolates of Escherichia coli in a university hospital in Istanbul, Turkey. J Clin Microbiol. 2008;46:1110–1112
  60. Marcadé G, Deschamps C, Boyd A, Gautier V, Picard B, Branger C, et al. Replicon typing of plasmids in Escherichia coli producing extended-spectrum β-lactamases. J Antimicrob Chemother. 2009;63:67–71
  61. Coque TM, Novais A, Carattoli A, Poirel L, Pitout J, Peixe L, et al. Dissemination of clonally related Escherichia coli strains expressing extended-spectrum β-lactamase CTX-M-15. Emerg Infect Dis. 2008;14:195–200
  62. Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V, Demarty R, Alonso MP, Caniça MM, et al. Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J Antimicrob Chemother. 2008;61:273–281
  63. Mitsuda T, Muto T, Yamada M, Kobayashi N, Toba M, Aihara Y, et al. Epidemiological study of a food-borne outbreak of enterotoxigenic Escherichia coli O25:NM by pulsed-field gel electrophoresis and randomly amplified polymorphic DNA analysis. J Clin Microbiol. 1998;36:652–656
  64. Sullivan CB, Diggle MA, Clarke SC. Multilocus sequence typing: data analysis in clinical microbiology and public health. Mol Biotechnol. 2005;29:245–254
  65. Clermont O, Dhanji H, Upton M, Gibreel T, Fox A, Boyd D, et al. Rapid detection of the O25b-ST131 clone of Escherichia coli encompassing the CTX-M-15-producing strains. J Antimicrob Chemother. 2009;64:274–277
  66. Johnson JR, Menard M, Johnston B, Kuskowski MA, Nichol K, Zhanel GG. Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004. Antimicrob Agents Chemother. 2009;53:2733–2739
  67. Blanco M, Alonso MP, Nicolas-Chanoine MH, Dahbi G, Mora A, Blanco JE, et al. Molecular epidemiology of Escherichia coli producing extended-spectrum β-lactamases in Lugo (Spain): dissemination of clone O25b:H4-ST131 producing CTX-M-15. J Antimicrob Chemother. 2009;63:1135–1141
  68. Lau SH, Kaufmann ME, Livermore DM, Woodford N, Willshaw GA, Cheasty T, et al. UK epidemic Escherichia coli strains A–E, with CTX-M-15 β-lactamase, all belong to the international O25:H4-ST131 clone. J Antimicrob Chemother. 2008;62:1241–1244
  69. Cagnacci S, Gualco L, Debbia E, Schito GC, Marchese A. European emergence of ciprofloxacin-resistant Escherichia coli clonal groups O25:H4-ST 131 and O15:K52:H1 causing community-acquired uncomplicated cystitis. J Clin Microbiol. 2008;46:2605–2612
  70. Yumuk Z, Afacan G, Nicolas-Chanoine MH, Sotto A, Lavigne JP. Turkey: a further country concerned by community-acquired Escherichia coli clone O25-ST131 producing CTX-M-15. J Antimicrob Chemother. 2008;62:284–288
  71. Literacka E, Bedenic B, Baraniak A, Fiett J, Tonkic M, Jajic-Bencic I, et al. blaCTX-M genes in Escherichia coli strains from Croatian hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a, blaCTX-M-15) genetic structures. Antimicrob Agents Chemother. 2009;53:1630–1635
  72. Suzuki S, Shibata N, Yamane K, Wachino J, Ito K, Arakawa Y. Change in the prevalence of extended-spectrum-β-lactamase-producing Escherichia coli in Japan by clonal spread. J Antimicrob Chemother. 2009;63:72–79
  73. Johnson JR, Jorgensen JH, Lewis J, Robicsek A, Menard M, Clabots C, et al. CTX-M-15-producing E. coli in the United States: predominance of sequence type ST131 (O25:H4). In: Proceedings of the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 25–28 October 2008, Washington, DC. Washington, DC: ASM Press; 2008;
  74. Naseer U, Haldorsen B, Tofteland S, Hegstad K, Scheutz F, Simonsen GS, et al. Molecular characterization of CTX-M-15-producing clinical isolates of Escherichia coli reveals the spread of multidrug-resistant ST131 (O25:H4) and ST964 (O102:H6) strains in Norway. APMIS. 2009;117:526–536
  75. Leflon-Guibout V, Blanco J, Amaqdouf K, Mora A, Guize L, Nicolas-Chanoine MH. Absence of CTX-M enzymes but high prevalence of clones, including clone ST131, among fecal Escherichia coli isolates from healthy subjects living in the area of Paris, France. J Clin Microbiol. 2008;46:3900–3905
  76. Arpin C, Quentin C, Grobost F, Cambau E, Robert J, Dubois V, et al. Nationwide survey of extended-spectrum β-lactamase-producing Enterobacteriaceae in the French community setting. J Antimicrob Chemother. 2009;63:1205–1214
  77. Oteo J, Diestra K, Juan C, Bautista V, Novais A, Pérez-Vázquez M, et al. Extended-spectrum β-lactamase-producing Escherichia coli in Spain belong to a large variety of multilocus sequence typing types, including ST10 complex/A, ST23 complex/A and ST131/B2. Int J Antimicrob Agents. 2009;34:173–176
  78. Rooney PJ, O’Leary MC, Loughrey AC, McCalmont M, Smyth B, Donaghy P, et al. Nursing homes as a reservoir of extended-spectrum β-lactamase (ESBL)-producing ciprofloxacin-resistant Escherichia coli. J Antimicrob Chemother. 2009;64:635–641
  79. Pomba C, da Fonseca JD, Baptista BC, Correia JD, Martinez-Martinez L. Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6′)-Ib-cr genes in a dog. Antimicrob Agents Chemother. 2009;53:327–328
  80. Woodford N, Carattoli A, Karisik E, Underwood A, Ellington MJ, Livermore DM. Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone. Antimicrob Agents Chemother. 2009;53:4472–4482
  81. Freeman JT, McBride SJ, Heffernan H, Bathgate T, Pope C, Ellis-Pegler RB. Community-onset genitourinary tract infection due to CTX-M-15-producing Escherichia coli among travelers to the Indian subcontinent in New Zealand. Clin Infect Dis. 2008;47:689–692
  82. Pitout JD, Campbell L, Church DL, Gregson DB, Laupland KB. Molecular characteristics of travel-related extended-spectrum-β-lactamase-producing Escherichia coli isolates from the Calgary Health Region. Antimicrob Agents Chemother. 2009;53:2539–2543
  83. Pitout JD, Gregson DB, Campbell L, Laupland KB. Molecular characteristics of extended-spectrum-β-lactamase-producing Escherichia coli isolates causing bacteremia in the Calgary Health Region from 2000 to 2007: emergence of clone ST131 as a cause of community-acquired infections. Antimicrob Agents Chemother. 2009;53:2846–2851
  84. Hawser SP, Bouchillon SK, Hoban DJ, Badal RE. In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005–2007: results from the SMART study. Int J Antimicrob Agents. 2009;34:585–588
  85. Hawser SP, Bouchillon SK, Hoban DJ, Badal RE, Hsueh PR, Paterson DL. Emergence of high levels of extended-spectrum-β-lactamase-producing Gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. Antimicrob Agents Chemother. 2009;53:3280–3284

PII: S0924-8579(09)00513-5

doi: 10.1016/j.ijantimicag.2009.11.003

International Journal of Antimicrobial Agents
Volume 35, Issue 4 , Pages 316-321 , April 2010

Article Tools